Agos­ti­ni Ltd has tak­en an­oth­er cal­cu­lat­ed step in its re­gion­al ex­pan­sion strat­e­gy, fi­nal­is­ing the ac­qui­si­tion of Massy Dis­tri­b­u­tion (Ja­maica) Ltd in a trans­ac­tion that sig­nif­i­cant­ly strength­ens its foot­print in the Ja­maican dis­tri­b­u­tion mar­ket.

The deal, first an­nounced more than a year ago, is ex­pect­ed to be­come ef­fec­tive to­day (March 1) fol­low­ing the is­suance of a state­ment of non-ob­jec­tion by Ja­maica’s Fair Trad­ing Com­mis­sion (FTC). Reg­u­la­to­ry clear­ance was not au­to­mat­ic. It came with spe­cif­ic con­di­tions aimed at pre­serv­ing the com­pet­i­tive bal­ance in a strate­gi­cal­ly im­por­tant seg­ment of Ja­maica’s phar­ma­ceu­ti­cal mar­ket.

While the pur­chase price has not been dis­closed, the scale of the ac­qui­si­tion is ev­i­dent. Ac­cord­ing to its par­ent, Massy Hold­ings Ltd, the Ja­maican sub­sidiary car­ried net as­sets of at least $179.87 mil­lion.

The ac­qui­si­tion is be­ing ex­e­cut­ed by Aca­do Ja­maica Hold­ings Ltd, a sub­sidiary of Aca­do Ltd, which is a 50/50 joint ven­ture be­tween Agos­ti­ni and Bar­ba­dos-based God­dard En­ter­pris­es Ltd.

That own­er­ship struc­ture is sig­nif­i­cant. It re­flects a de­lib­er­ate joint-ven­ture strat­e­gy be­tween two es­tab­lished Caribbean con­glom­er­ates seek­ing scale in dis­tri­b­u­tion across the re­gion.

The Ja­maican trans­ac­tion builds on Agos­ti­ni’s Au­gust 2023 ac­qui­si­tion of Aven­ta Ja­maica, while com­ple­ment­ing God­dard’s ex­ist­ing com­mer­cial in­ter­ests in Ja­maica span­ning au­to­mo­tive, cater­ing and la­bel print­ing ser­vices.

How­ev­er, the FTC’s ap­proval was con­di­tion­al. As part of the trans­ac­tion, Aven­ta Ja­maica Ltd will dis­con­tin­ue dis­tri­b­u­tion of the Eli Lil­ly in­sulin port­fo­lio, once tran­si­tion arrange­ments are com­plet­ed.

Ac­cord­ing to the FTC re­port, Aven­ta dis­trib­uted ap­prox­i­mate­ly J$30 bil­lion (US$190 mil­lion) of in­ter­me­di­ate-act­ing in­sulin in 2024, rep­re­sent­ing an es­ti­mat­ed 81 per cent mar­ket share.

The com­bined con­cen­tra­tion of Aven­ta and Massy Dis­tri­b­u­tion (Ja­maica) across the coun­try’s three in­sulin brands ef­fec­tive­ly rep­re­sent­ed a reg­u­la­to­ry ceil­ing for the FTC. From the Com­mis­sion’s per­spec­tive, per­mit­ting fur­ther con­sol­i­da­tion in a mar­ket tied to a life-sus­tain­ing prod­uct would have risked en­trench­ing dom­i­nance be­yond ac­cept­able com­pet­i­tive thresh­olds.

To mit­i­gate the risk of ex­ces­sive mar­ket dom­i­nance, the FTC pro­vid­ed Aca­do with three op­tions to com­plete the ac­qui­si­tion. Cari-Med Group Ltd has been pro­posed as the new dis­trib­u­tor of the Eli Lil­ly port­fo­lio, with the tran­si­tion ex­pect­ed to be com­plet­ed by Sep­tem­ber 2026.

Cari-Med is wide­ly re­gard­ed as Ja­maica’s dom­i­nant phar­ma­ceu­ti­cal dis­trib­u­tor and was found­ed by Glen Chris­t­ian, a for­mer 16-year em­ploy­ee of Massy Dis­tri­b­u­tion (Ja­maica).

From Agos­ti­ni’s stand­point, re­lin­quish­ing the Eli Lil­ly line rep­re­sents a com­mer­cial con­ces­sion. Yet such con­ces­sions are of­ten the price of reg­u­la­to­ry ap­proval in con­cen­trat­ed mar­kets. More­over, dis­tri­b­u­tion port­fo­lios are rarely sta­t­ic. It is plau­si­ble that Swiss brands cur­rent­ly dis­trib­uted by Cari-Med could mi­grate to the new­ly ac­quired plat­form, while God­dard’s McBride (Caribbean) port­fo­lio may shift from Amal­ga­mat­ed Dis­trib­u­tors Ltd to Massy Dis­tri­b­u­tion (Ja­maica), there­by restor­ing scale with­in the en­larged op­er­a­tion.

Be­yond the im­me­di­ate me­chan­ics of the trans­ac­tion, the ac­qui­si­tion re­flects a broad­er and more de­lib­er­ate deep­en­ing of Ja­maican ties by the share­hold­ers of Aca­do Ltd.

That com­mit­ment is not re­cent. Ja­maican ex­ec­u­tive Joan­na Banks was ap­point­ed to Agos­ti­ni’s board in April 2021, sig­nalling ear­ly recog­ni­tion of the strate­gic im­por­tance of the Ja­maican mar­ket in­sight at the par­ent-com­pa­ny lev­el. More re­cent­ly, in Jan­u­ary 2026, Steven Good­en joined God­dard’s board, re­in­forc­ing a sim­i­lar gov­er­nance em­pha­sis with­in the Bar­ba­dos-based con­glom­er­ate.

Sales by Agos­ti­ni, which is chaired by Chris­t­ian Mout­tet, in­creased by 7 per cent in 2025 to $5.4 bil­lion, while prof­it at­trib­ut­able to share­hold­ers rose by 10 per cent from $210 to $230 mil­lion.

Massy’s rev­enue in 2025 to­talled $15.8 bil­lion in 2025, which was a three per cent in­crease over 2024. The group’s af­ter-tax prof­it in 2025 amount­ed to $778 mil­lion, a nine per cent in­crease over 2024. James McLetchie was pro­mot­ed to pres­i­dent and group CEO of Massy ef­fec­tive Oc­to­ber 1, 2025, fol­low­ing the re­tire­ment of David Af­fon­so.